Medicalization of aging and the testosterone deficiency syndrome

16 Dec

Over the last few years it has been proposed that the simple fact of having testosterone below the normal levels, which occurs with the passage of time, provokes a constellation of disorders. Testosterone therapy in the management of TDS (testosterone deficiency syndrome) is not justified, because there is no clear benefit in the relevant primary endpoints and there are alarming results on the possible risks.
Increasing consumption responds to the success of awareness raising campaigns. TDS is a clear example of disease mongering.

  • Medicalization of aging and the testosterone deficiency syndrome. Gérvas, J., Gavilán, E., Gorricho, J. BIT Navarra. 2012;20 (4):1-8. Download article here.

See also a “letter” about the same topic published by the authors in BMJ:

  • Marketing, not evidence based arguments has probably increased testosterone prescribing. Gorricho, J., Gavilán, E., Gérvas, J. BMJ 2012; 345: e6905 doi: 10.1136/bmj.e6905 (Published 17 October 2012). Download letter here.